– SAN DIEGO–(BUSINESS WIRE)–Jun. 16, 2016– Illumina, Inc. (NASDAQ: ILMN) today announced that it has signed deals with 12 customers for its new Infinium® Global Screening Array (GSA). In total, the company has received orders for more than 3 million samples of the new consortia-developed array. Initial customers include human disease researchers at The Broad Institute and deCODE Genetics, health systems Avera Health, Codigo46, Diagnomics, Eone Diagnomics Genome Center (EDGC), Sanford Health and UCLA Health System, genomic service providers Centre National de Genotypage, Human Genomics Facility HuGeF, Erasmus MC, Life and Brain, and consumer genomics company 23andMe, Inc.

http://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=2178011